LGI1 encephalitis manifesting as a delayed paraneoplastic response of squamous cell lung cancer on remission.

Oxf Med Case Reports

Department of Neurology, New Cross Hospital, Royal Wolverhampton NHS Trust, Wolverhampton Road, Heath Town, West Midlands, WV10 0QP, United Kingdom.

Published: December 2024

The leucine-rich glioma-inactivated protein 1 (LGI1) antibody-related autoimmune encephalitis can occur alone or in the setting of a malignancy and manifest with faciobrachial dystonic seizures (FBDS), cognitive decline, hyponatremia, and neuropsychiatric disorders. The importance of differentiating this entity from acute delirium cannot be overemphasized. This review provides a detailed account of a 71-year-old man with previous diagnosis of lung cancer who presented with subacute onset behavioural changes, urinary retention, and FBDS. Investigation revealed hyponatremia, bilateral mesial temporal lobe high signal abnormality worse on the right on MRI and CSF positive anti-LGI1 antibodies (1:30). The patient was treated with immunosuppressive therapy with consequent symptom improvement. This case emphasizes the need to have a high index of suspicion for this disease entity in patients presenting with new onset behavioural changes and the importance of identifying the typical FBDS, as early initiation of treatment confers a positive outcome for diseased patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682483PMC
http://dx.doi.org/10.1093/omcr/omae171DOI Listing

Publication Analysis

Top Keywords

lung cancer
8
onset behavioural
8
behavioural changes
8
lgi1 encephalitis
4
encephalitis manifesting
4
manifesting delayed
4
delayed paraneoplastic
4
paraneoplastic response
4
response squamous
4
squamous cell
4

Similar Publications

Lung cancer remains the leading cause of cancer-related deaths worldwide due to its poor prognosis. Despite significant advancements in the understanding of cancer development, improvements in diagnostic methods, and multimodal therapeutic regimens, the prognosis of lung cancer has still not improved. Therefore, it is reasonable to look for newer and alternative medicines for treatment.

View Article and Find Full Text PDF

Introduction: Lung cancer ranks among the foremost causes of mortality associated with cancer. Ensartinib is a highly effective oral anaplastic lymphoma kinase (ALK) inhibitor utilized in the treatment of ALK-positive lung adenocarcinoma. This report presents a case of acute renal failure attributed to the administration of ensartinib.

View Article and Find Full Text PDF

Background: Accurate data on the prognosis of bone metastases are necessary for appropriate treatment. Immune checkpoint inhibitors (ICIs) are widely used in the treatment of gene mutation-negative non-small cell lung cancer (GMN-NSCLC).

Aim: To investigate the prognostic factors in patients with bone metastases from GMN-NSCLC following ICI use.

View Article and Find Full Text PDF

Ion channels, as functional molecules that regulate the flow of ions across cell membranes, have emerged as a promising target in cancer therapy due to their pivotal roles in cell proliferation, metastasis, apoptosis, drug resistance, and so on. Recently, increasing evidence suggests that dysregulation of ion channels is a common characteristic of cancer cells, contributing to their survival and the resistance to conventional therapies. For example, the aberrant expression of sodium (Na) and potassium ion (K) channels is significantly correlated with the sensitivity of chemotherapy drugs.

View Article and Find Full Text PDF

Pembrolizumab (an anti-PD1 antibody) alone or combined with chemotherapy represented the standard of care for advanced non-oncogene addicted non-small cell lung cancer (NSCLC) patients. These therapies induced early modifications of the immune response impacting the clinical outcome. Identifying early changes in the immune system was critical to directing the therapeutic choice and improving the clinical outcome.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!